期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

尿激酶型纤溶酶原激活因子基因P141L多态性与迟发性阿尔茨海默病的关系 被引量：3

Relation between the P141L Polymorphism of Urokinase Plasminogen Activator Gene and Late-onset Alzheimer's Disease
暂未订购
导出
摘要 目的探讨尿激酶型纤溶酶原激活因子基因(PLAU)P141L多态性与中国汉族人群迟发性阿尔茨海默病(Late-onset Alzheimer’sdisease,LOAD)的关系。方法采用DSM-Ⅳ诊断标准和NINCDS-ADRDA诊断标准中"很可能AD"的标准,选择67例LOAD患者,与71例年龄、性别与AD组匹配的健康对照者进行病例对照研究;采用聚合酶链反应限制性片段长度多态性(PCR-RFLP)技术,检测PLAU基因P141L多态性并进行关联分析。结果LOAD组与对照组基因型分布频率均符合Hardy-Weinberg定律;两组基因型分布差异无统计学意义(χ2=0.3278,P=0.8488);两组等位基因分布差异无统计学意义(χ2=0.2238,P=0.6361)。结论PLAU基因P141L多态性与中国汉族人群LOAD未发现存在关联。 Objective To explore the relation between the P141L polymorphism of urokinase plasminogen activator gene(PLAU) and Late-onset Alzheimer s disease(LOAD) in Hans.Methods A total of 67 LOAD patients based on the diagnosis standard of DSM-Ⅳ and NINCDS-ADRDA and 71 subjects of the same age and the same sex construction as those in the case group were enrolled in this case-control study.The polymerase chain reaction-restriction fragment length polymorphism(PCR-RFLP) technique was used in detecting the polymorphis...
作者 向绍通 徐书雯 李东风
机构地区 广东省人民医院老年医学研究所神经内科 广东省人民医院医学研究中心
出处 《首都医科大学学报》 CAS 2008年第3期278-282,共5页 Journal of Capital Medical University
基金 2005年度广东省自然科学基金自由申请项目(5001277)~~
关键词 阿尔茨海默病 尿激酶型纤溶酶原激活因子 基因多态性 聚合酶链反应 限制性片段长度多态性 Alzheimer disease urokinase plasminogen activator polymerase chain reaction restriction fragment length
分类号 R749.16 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献16

  • 1[1]Ledesma M D,Abad-Rodrigue J,Galvan C,et al.Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains[J].EMBO,2003,4:1190-1196.
  • 2[2]Ledesma M D,Da Silva J S,Crassaerts K,et al.Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduceed in Alzheimer's disease brains[J].EMBO Rep,2000,1:530-535.
  • 3汤荟冬,陈雪华,陈生弟.神经生长因子对β-淀粉样蛋白_(25-35)诱导海马细胞毒性的防治作用[J].中国临床康复,2002,6(13):1906-1907. 被引量：22
  • 4[4]Flood J F,Morley J E,Roberts E.Amnestic effects in mice of four synthetic peptides homologous to amyloid beta protein from patients with Alzheimer disease[J].Proc Natl Acad Sci USA,1991,88:3363-3366.
  • 5[5]Levites Y,Das P,Price R W,et al.Anti-Aβ42 and anti-Aβ40 specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model[J].J Clin Invest,2006,116:193-201.
  • 6[6]Brendza R P,Bacskai B J,Cirrito J R,et al.Anti-Aβ antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice[J].J Clin Invest,2005,115:428-433.
  • 7[7]Rajput B,Degen S F,Reich E,et al.Chromosomal locations of human tissue plasminogen activator and urokinase genes[J].Science,1985,230:672-674.
  • 8[8]Tucker H M,Kihiko M.The plasmin system is induced by and degrades amyloid-bete aggregates[J].Neurosci,2000,20:3937-3946.
  • 9[9]Tucker H M,Kihiko M,Estus S,et al.Urokinase-type plasminogen activator inhibits Amyloid-β neurotoxicity and fibrillogenesis via plasminogen[J].J Neurosci Res,2002,70:249-255.
  • 10[10]Finckh U,van Hadeln K,Muller-Thomsen T,et al.Association of late-onset Alz-Heimer disease with a genotype of PLAU,the gene encoding urokinase-type plas-minogen activator on chromosome 10q22.2[J].Neurogenetics,2003,4:213-217.

二级参考文献2

共引文献21

同被引文献34

  • 1商秀丽,张凤英,孟令慧,张蔚,林梅青,薛一雪.阿尔茨海默病患者血尿酸水平的检测及意义[J].中国医科大学学报,2009,38(5):333-334. 被引量：13
  • 2彭丹涛,许贤豪,褚德发.老年性痴呆患者血浆中β淀粉样蛋白Aβ_(1-42)和Aβ_(1-40)水平与对照组的对比研究[J].中华老年心脑血管病杂志,2004,6(6):371-373. 被引量：3
  • 3曾志荣,周韶璋,廖山婴,陈斌,李初俊,陈旻湖,胡品津.白介素8-251位点基因多态性与我国高低发区胃癌关系[J].中山大学学报（医学科学版）,2005,26(5):537-540. 被引量：12
  • 4Nobili F,Vitali P,Canfora M,et al.Effects of long-termDonepezil therapy on rCBF of Alzheimer's patients[J].Clin Neurophysiol,2002,113(8):1241-1248.
  • 5Ledesma M D,Abad-Rodriguez J,Galvan C,et al.Raft dis-organization leads to reduced plasmin activity in Alzheimer'sdisease brains[J].EMBO Rep,2003,4(12):1190-1196.
  • 6Alonso D F,Farias E F,Famulari A L,et al.Excessive u-rokinase-type plasminogen activator activity in the euglobu-lin fraction of patients with Alzheimer-type dementia[J].JNeurol Sci,1996,139(1):83-88.
  • 7Tiemey M C,Fisher R H,Lewis A J,et al.The NINCDS-ADRDA Work Group criteria for the clinical diagnosis ofprobable Alzheimer's disease:a clinicopathologic study of57 cases[J].Neurology,1988,38(3):359-364.
  • 8Blacker D,Albert M S,Bassett S S,et al.Reliability andvalidity of NINCDS-ADRDA criteria for Alzheimer's dis-ease.The National Institute of Mental Health Genetics Ini-tiative[J].Arch Neurol,1994,51(12):1198-1204.
  • 9Ledesma M D,Da Silva J S,Crassaerts K,et al.Brainplasmin enhances APP alpha-cleavage and Abeta degrada-tion and is reduceed in Alzheimer's disease brains[J].EM-BO Rep,2000,1(6):530-535.
  • 10Tucker H M,Kihiko-Ehmann M,Estus S,et al.Uroki-nase-type plasminogen activator inhibits amyloid-βneuro-toxicity and fibrillogenesis via plasminogen[J].J NeurosciRes,2002,70(2):249-255.

引证文献3

二级引证文献1

首都医科大学学报
2008年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部